{"id":3252,"date":"2017-10-24T16:47:05","date_gmt":"2017-10-24T20:47:05","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3252"},"modified":"2017-10-24T16:49:28","modified_gmt":"2017-10-24T20:49:28","slug":"secondaries-announced-10-24-17","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-10-24-17\/","title":{"rendered":"Secondaries Announced 10.24.17"},"content":{"rendered":"<h4><strong>IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis.<\/strong><\/h4>\n<p>If having\u00a0<a href=\"http:\/\/www.ipoboutique.com\/blog\/ipo-boutique-announces-new-secondary-alert-service\/#sthash.HnSepMmy.dpbs\" target=\"_blank\"><strong>real-time alerts for secondary offerings<\/strong><\/a>\u00a0would be an advantage to you,<a style=\"border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: #333333; color: #333333; text-decoration: none;\" href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">\u00a0inquire about a subscription today!<\/a><\/p>\n<p>Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.<\/p>\n<p>Company:<strong> Idera Pharmaceuticals<\/strong><br \/>\nSymbol: IDRA<br \/>\nPrice: Last Trade $2.18<br \/>\nTrade Date: 10\/26<br \/>\nShares: 27.5 million ($60 million cash raise)<br \/>\nUnderwriter(s) : J.P. Morgan, Goldman Sachs &amp; Co., Barclays<br \/>\nDescription: Harnessing the approach of the earliest researchers in immunotherapy and the company\u2019s vast experience in developing proprietary immunology platforms, Idera\u2019s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: <strong>Savara, Inc.<\/strong><br \/>\nSymbol: SVRA<br \/>\nPrice: Last Trade $9.21<br \/>\nTrade Date: 10\/25<br \/>\nShares: 4.9 million ($45m cash raise)<br \/>\nRe-Offer Range: <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><br \/>\nUnderwriter(s) : Jefferies, JMP Securities, Canaccord Genuity<br \/>\nCo-Manager(s): H.C. Wainwright &amp; Co., Roth Capital<br \/>\nDescription: Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: <strong>Scorpio Bulkers, Inc.<\/strong><br \/>\nSymbol: SALT<br \/>\nPrice: Last Trade $8.35<br \/>\nTrade Date: 10\/25<br \/>\nShares: 10.0 million<br \/>\nRe-Offer Range: <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><br \/>\nUnderwriter(s) : Morgan Stanley<br \/>\nCo-Manager(s):Clarksons Platou Securities, Seaport Global<br \/>\nDescription: Scorpio Bulkers Inc. is a provider of marine transportation of dry bulk commodities. Scorpio Bulkers Inc., after the completion of its recent acquisition of six Ultramax vessels, will own 52 vessels, consisting of 18 Kamsarmax vessels and 34 Ultramax vessels.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: <strong>Camping World Holdings<\/strong><br \/>\nSymbol: CWH<br \/>\nPrice: Last Trade $42.86<br \/>\nTrade Date: 10\/26<br \/>\nShares: 6.7 million<br \/>\nUnderwriter(s) : Goldman Sachs &amp; Co., J.P. Morgan, BofA Merrill Lynch, Credit Suisse<br \/>\nCo-Manager(s): Baird, BMO, KeyBanc Capital, Stephens, Wells Fargo<br \/>\nDescription: They believe they are the only provider of a comprehensive portfolio of services, protection plans, products and resources for recreational vehicle enthusiasts.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: <strong>Sunesis Pharmaceuticals, Inc.<\/strong><br \/>\nSymbol: SNSS<br \/>\nPrice: Last Trade $1.85<br \/>\nTrade Date: 10\/25<br \/>\nShares: 8.1 million ($15 million cash raise)<br \/>\nRe-Offer Range:<strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><br \/>\nUnderwriter(s) : Cowen, Wells Fargo<br \/>\nCo-Manager(s): Oppenheimer &amp; Co.<br \/>\nDescription: Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: <strong>PennantPark Floating Rate Capital Ltd.<\/strong><br \/>\nSymbol: PFLT<br \/>\nPrice: Last Trade $14.59<br \/>\nTrade Date: 10\/25<br \/>\nShares: 6 million<br \/>\nRe-Offer Range: <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><br \/>\nUnderwriter(s) : Morgan Stanley, Goldman Sachs &amp; Co., J.P. Morgan, Keefe Bruyette &amp; Woods, RBC Capital, SunTrust Robinson Humphrey<br \/>\nDescription: PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market private companies in the form of floating rate senior secured loans.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n<p>Company: <strong>Hutchison China MediTech Ltd.<\/strong><br \/>\nSymbol: HCM<br \/>\nPrice: Last Trade $27.69<br \/>\nTrade Date: 10\/26<br \/>\nShares: 9.5 million ($262m cash raise)<br \/>\nUnderwriter(s) : BofA Merrill Lynch, Deutsche Bank<br \/>\nCo-Manager(s): Stifel, Canaccord Genuity, Panmure Gordon, CITIC CLSA<br \/>\nDescription: Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.<br \/>\nRating = <strong><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">Subscription Needed<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis. If having\u00a0real-time alerts for secondary offerings\u00a0would be an advantage to you,\u00a0inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[],"class_list":["post-3252","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3252"}],"version-history":[{"count":3,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3252\/revisions"}],"predecessor-version":[{"id":3255,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3252\/revisions\/3255"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}